Neuphoria Therapeutics Inc.
NEUP
$4.84
-$0.11-2.22%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 662.70K | -- | -- | 7.40K | 14.90K |
| Total Other Revenue | -95.70K | -95.70K | -95.70K | -91.50K | -88.70K |
| Total Revenue | 567.00K | -95.70K | -95.70K | -91.50K | -88.70K |
| Cost of Revenue | -1.46M | -1.16M | 24.20K | -978.00K | -2.07M |
| Gross Profit | 2.03M | 1.07M | -119.90K | 886.50K | 1.98M |
| SG&A Expenses | 8.71M | 8.60M | 9.31M | 10.19M | 11.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.26M | 16.66M | 18.56M | 20.10M | 21.50M |
| Operating Income | -15.70M | -16.76M | -18.66M | -20.19M | -21.59M |
| Income Before Tax | -8.24M | -10.90M | -15.47M | -18.17M | -20.72M |
| Income Tax Expenses | -137.60K | -184.00K | -86.60K | -113.50K | -139.30K |
| Earnings from Continuing Operations | -8.10 | -10.71 | -15.38 | -18.06 | -20.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.10M | -10.71M | -15.38M | -18.06M | -20.58M |
| EBIT | -15.70M | -16.76M | -18.66M | -20.19M | -21.59M |
| EBITDA | -15.17M | -16.23M | -18.13M | -19.69M | -21.02M |
| EPS Basic | -1.24 | -5.32 | -5.32 | -5.32 | -5.32 |
| Normalized Basic EPS | -0.77 | -3.35 | -3.35 | -3.35 | -3.35 |
| EPS Diluted | -1.24 | -5.32 | -5.32 | -5.32 | -5.32 |
| Normalized Diluted EPS | -0.77 | -3.35 | -3.35 | -3.35 | -3.35 |
| Average Basic Shares Outstanding | 6.58B | 6.58B | 5.27B | 4.97B | 4.67B |
| Average Diluted Shares Outstanding | 6.58B | 6.58B | 5.27B | 4.97B | 4.67B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
